- Home
- BBIO vs AKAM Comparison
BBIO vs AKAM Comparison
Compare BBIO & AKAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBIO
- AKAM
- Stock Information
- Founded
- BBIO 2015
- AKAM 1998
- Country
- BBIO United States
- AKAM United States
- Employees
- BBIO N/A
- AKAM N/A
- Industry
- BBIO Biotechnology: Pharmaceutical Preparations
- AKAM Business Services
- Sector
- BBIO Health Care
- AKAM Consumer Discretionary
- Exchange
- BBIO Nasdaq
- AKAM Nasdaq
- Market Cap
- BBIO 12.5B
- AKAM 11.4B
- IPO Year
- BBIO 2019
- AKAM 1999
- Fundamental
- Price
- BBIO $71.90
- AKAM $89.84
- Analyst Decision
- BBIO Strong Buy
- AKAM Hold
- Analyst Count
- BBIO 19
- AKAM 17
- Target Price
- BBIO $74.79
- AKAM $93.00
- AVG Volume (30 Days)
- BBIO 2.4M
- AKAM 4.6M
- Earning Date
- BBIO 10-29-2025
- AKAM 11-06-2025
- Dividend Yield
- BBIO N/A
- AKAM N/A
- EPS Growth
- BBIO N/A
- AKAM 0.97
- EPS
- BBIO N/A
- AKAM 3.41
- Revenue
- BBIO $353,780,000.00
- AKAM $4,133,202,000.00
- Revenue This Year
- BBIO $123.32
- AKAM $6.69
- Revenue Next Year
- BBIO $73.46
- AKAM $5.12
- P/E Ratio
- BBIO N/A
- AKAM $26.21
- Revenue Growth
- BBIO 62.46
- AKAM 4.21
- 52 Week Low
- BBIO $25.34
- AKAM $67.51
- 52 Week High
- BBIO $72.26
- AKAM $103.75
- Technical
- Relative Strength Index (RSI)
- BBIO 71.58
- AKAM 66.27
- Support Level
- BBIO $64.41
- AKAM $87.33
- Resistance Level
- BBIO $67.71
- AKAM $91.01
- Average True Range (ATR)
- BBIO 2.80
- AKAM 3.42
- MACD
- BBIO 0.35
- AKAM 0.32
- Stochastic Oscillator
- BBIO 95.73
- AKAM 84.92
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
About AKAM Akamai Technologies Inc.
Akamai operates a content delivery network, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,100 points of presence in more than 1,000 cities worldwide. The firm also offers security and cloud computing for its customers, and those businesses have grown to be bigger than the legacy CDN.